The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI

Thrombosis and Haemostasis

Volumn 109, Issue 4, 2013, Pages 606-613

  Raps, Marjolein ^a   Helmerhorst, Frans M ^a   Fleischer, Kathrin ^b   Dahm, Anders E A ^c   Rosendaal, Frits R ^a   Rosing, Jan ^d   Reitsma, Pieter ^a   Sandset, Per Morten ^c   van Vliet, Huib A A M ^a,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

Author keywords

APC resistance; Deep vein thrombosis; Oral contraceptives; Protein C S pathway; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

ACTIVATED PROTEIN C; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; COPPER INTRAUTERINE DEVICE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; INTRAUTERINE DEVICES, COPPER; LIPOPROTEINS; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84875137668     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-10-0771     Document Type: Article

References (45)

1. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Eng J Med 2001; 344: 1527-1534.
2. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, et al. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371-1380.
3. Van Hylckama Vlieg A, Helmerhorst FM, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. Br Med J 2009; 339: b2921.
4. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. Br Med J 2009; 339: b2890.
5. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel-and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
6. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-2040.
7. Van Vliet HA, Winkel TA, Noort I, et al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2062.
8. Tchaikovski SN, Van Vliet HA, Thomassen MC, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007; 98: 1350-1356.
9. Parkin L, Sharples K, Hernandez RK, et al. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. Br Med J 2011; 342: d2139.
10. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. Br Med J 2011; 342: d2151.
11. Van Vliet HA, Winkel TA, Noort I, et al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2062.
12. Van Vliet HA, Bertina RM, Dahm AE, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008; 6: 346-351.
13. De Visser MC, Van Hylckama Vlieg A, Tans G, et al. Determinants of the APTTand ETP-based APC sensitivity tests. J Thromb Haemost 2005; 3: 1488-1494.
14. Hoibraaten E, Mowinckel MC, De Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001; 115: 415-420.
15. Bajaj MS, Kuppuswamy MN, Manepalli AN, et al. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82: 1047-1052.
16. Broze GJ, Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
17. Hackeng TM, Maurissen LF, Castoldi E, et al. Regulation of TFPI function by protein S. J Thromb Haemost 2009; 7 (Suppl 1): 165-168.
18. Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost 1999; 82: 601-609.
19. Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 2009; 29: 2015-2020.
20. Castoldi E, Simioni P, Tormene D, et al. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost 2010; 8: 294-300.
21. Dahm AE, Sandset PM, Rosendaal FR. The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost 2008; 6: 393-395.
22. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103: 3106-3111.
23. Dielis AW, Castoldi E, Spronk HM, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-131.
24. Van Vliet HA, Tchaikovski SN, Rosendaal FR, et al. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). Thromb Haemost 2009; 101: 691-695.
25. Van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2062.
26. Van Vliet HA, Rodrigues SP, Snieders MN, et al. Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden. Thromb Res 2008; 121: 757-761.
27. Fleischer K, Van Vliet HA, Rosendaal FR, et al. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res 2009; 123: 429-435.
28. WHO. Medical eligibility criteria for contraceptive use. 4th ed. Geneva: WHO; 2009. Available at http: //www.who.int/reproductivehealth/publications/ family_planning/9789241563888/en/index.html. 2011.
29. Van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2062.
30. Giri TK, Hillarp A, Hardig Y, Zoller B, Dahlback B. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998; 79: 767-772.
31. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-4392.
32. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second-and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-238.
33. Van Vliet HA, Winkel TA, Noort I, et al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2062.
34. Raps M, Helmerhorst F, Fleischer K, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost 2012; 10: 992-997.
35. Van Hylckama Vlieg A, Helmerhorst FM, et al. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30: 2297-2300.
36. Lidegaard O, Nielsen LH, Skovlund CW, et al. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. Br Med J 2012; 344: e2990.
37. Alhenc-Gelas M, Plu-Bureau, Guillonneau S, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004; 2: 1594-1600.
38. Koenen RR, Christella M, Thomassen LG, et al. Effect of oral contraceptives on the anticoagulant activity of protein S in plasma. Thromb Haemost 2005; 93: 853-859.
39. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second-and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004; 103: 927-933.
40. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003; 67: 173-185.
41. Kluft C, Endrikat J, Mulder SM, et al. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 2006; 73: 336-343.
42. Johnson JV, Lowell J, Badger GJ, et al. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 2008; 111: 278-284.
43. Jensen JT, Burke AE, Barnhart KT, et al. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception 2008; 78: 451-458.
44. Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. Br Med J 2011; 343: d6423.
45. Carlsson S, Dahlback B. Dependence on vitamin K-dependent protein S for eukaryotic cell secretion of the beta-chain of C4b-binding protein. J Biol Chem 2010; 285: 32038-32046.